jump to search | jump to navigation

Elan investigates the spin-out of public drug delivery unit

20.04.10 Dublin – Irish neuroscience specialist Elan Corporation plc has announced it is investigating the option of spinning out its Elan Drug Technologies business, creating two publicly listed enterprises. Elan is currently assessing... more
 

Elan finds biomarker to monitor Alzheimer’s plaques

02.03.10 Dublin – The Elan Corporation has established a novel biomarker, 11C-PiB PET, that can detect whether Alzheimer drug candidates can reduce pathogenic beta-amyloid plaques in the brains of patients. With the new marker, Elan... more
 

EU regulatory authority reviews Biogen/Elan MS drug after steep increase in brain infections

26.10.09 Dublin/Boston – The risk-benefit ratio of Biogen/Elan’s co-marketed multiple sclerosis antibody drug Tysabri (natalizumab) is to be reviewed by the EU’s regulatory authority EMEA. The EMEA said on Friday that it has observed a... more
 

GSK cuts work-force

20.05.08 Currabinny – GlaxoSmithKline is to reduce its staff at Currabinny by 100 employees. Site director Finbar Whyte said that “due to falling volumes globally of some of our site’s products, we have excess capacity at Currabinny,” and... more
 

Sequencing market

19.03.08 Dublin – The global DNA sequencing market is projected to grow at 4.63% compounded annually from 2005 to 2012, according to an analysis released by Research and Markets at the beginning of March. The US and Europe are forerunners... more
 
Displaying results 1 to 5 out of 22

First Previous 1 2 3 4 5 Next Last

Metanavigation